Published in Behav Brain Res on March 19, 2014
Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep (2014) 0.88
Pathophysiology Associated with Traumatic Brain Injury: Current Treatments and Potential Novel Therapeutics. Cell Mol Neurobiol (2016) 0.86
Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function. J Physiol (2015) 0.82
Caveolins in cardioprotection - translatability and mechanisms. Br J Pharmacol (2015) 0.80
Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic Dysfunction. Acta Naturae (2017) 0.75
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 9.18
Statins and the risk of dementia. Lancet (2000) 5.65
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2011) 5.30
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol (2002) 2.18
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med (2004) 1.99
Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy (2003) 1.93
Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc (2013) 1.89
3-Hydroxy-3-methylglutaryl-CoA reductase: a transmembrane glycoprotein of the endoplasmic reticulum with N-linked "high-mannose" oligosaccharides. Proc Natl Acad Sci U S A (1983) 1.80
Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol (1991) 1.77
Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron (2011) 1.71
Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med (2011) 1.44
Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. Neuroscience (2009) 1.24
Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy (2009) 1.23
Loss of caveolin-1 accelerates neurodegeneration and aging. PLoS One (2010) 1.23
Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci (2010) 1.18
Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy (2003) 1.11
Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices. FEBS Lett (1990) 1.04
CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology (2008) 1.02
Cognitive effects of statin medications. CNS Drugs (2014) 0.93
Lipid rafts, synaptic transmission and plasticity: impact in age-related neurodegenerative diseases. Neuropharmacology (2012) 0.92
Short-term memory loss associated with rosuvastatin. Pharmacotherapy (2006) 0.90
The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother (2012) 0.89
Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res (2008) 0.87
Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider. Neurol Sci (2010) 0.84